
Bristol-Myers Squibb Company BMY
$ 60.74
-2.55%
Annual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Cash Conversion Cycle 2011-2026 | BMY
Annual Cash Conversion Cycle Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.6 | 60.4 | 62.2 | 48.1 | 42.9 | 88.2 | 191 | 57.6 | 45.6 | 72.9 | 62.6 | -8.13 | -8.99 | 20.7 | -15.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 191 | -15.2 | 51.9 |
Quarterly Cash Conversion Cycle Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.1 | 66.8 | 73.6 | 64.6 | 65.3 | 65.2 | 61.4 | 57.3 | - | 29 | 18.6 | 38.8 | - | 31.8 | 22.6 | 44.1 | 70.1 | 50.3 | 55 | 83.6 | 88.3 | 211 | 197 | 132 | 89.5 | 57 | 56.3 | 56.5 | 106 | 109 | 112 | 110 | 96.5 | 103 | 104 | 102 | 91.5 | 96.4 | 94.2 | 86.8 | 72.7 | 78.9 | 79.5 | 80.8 | 69 | 75.4 | 75.7 | 76.7 | 67.1 | 75.3 | 63.3 | 59.3 | 62.6 | 63.9 | 62.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 211 | 18.6 | 77.1 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
355 | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | ||
|
AbCellera Biologics
ABCL
|
173 | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Anika Therapeutics
ANIK
|
270 | $ 14.19 | -1.18 % | $ 208 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
Aptorum Group Limited
APM
|
-400 | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Apellis Pharmaceuticals
APLS
|
115 | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
235 | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
AVEO Pharmaceuticals
AVEO
|
-123 | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
-256 | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
-114 | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | ||
|
Equillium
EQ
|
33.2 | $ 1.79 | 2.29 % | $ 62.2 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
BioMarin Pharmaceutical
BMRN
|
733 | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-6 K | $ 2.93 | -8.44 % | $ 1.05 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |